S-3 - Esperion Therapeutics, Inc. (0001434868) (Filer)

DEFA14A - Esperion Therapeutics, Inc. (0001434868) (Filer)

DEF 14A - Esperion Therapeutics, Inc. (0001434868) (Filer)

144 - Esperion Therapeutics, Inc. (0001434868) (Subject)

SCHEDULE 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

SCHEDULE 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-12) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-15) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 211616, Application Classification: Labeling

Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-19) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 211617, Application Classification: Labeling

Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-14) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 211616, Application Classification: Labeling

Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-18) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 211617, Application Classification: Labeling

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement – – Announces Development of Triple Combination Products with Bempedoic Acid in the U.S. – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 04, 2025 (GLOBE

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "The year to date has been transformational for Es

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for appro

– Total Revenue Increased 186% Year-over-Year to $73.8 Million withU.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Revenue Interest Facility – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported finan

ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be arc

ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archiv

– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Data and Reflect a Highly Differentiated Product Profile – – Positive CHMP Opinion Received; European Cardiovascular (CV) Risk Reduction Label Determination Anticipated in Q2 2024 – – Conference Call and Webcast on Monday, March 25 at 8:00 a.m. ET – Esperion (NASDAQ:ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on pos

– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Data and Reflect a Highly Differentiated Product Profile – – Positive CHMP Opinion Received; European Cardiovascular (CV) Risk Reduction Label Determination Anticipated in Q2 2024 – – Conference Call and Webcast on Monday, March 25 at 8:00 a.m. ET – ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (b

– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total Revenue Grew 72% Y/Y to $32.3 Million – – Q4 Retail Prescription Equivalents Grew 44% Y/Y and 8% Q/Q, with Momentum Expected into 1H 2024 – – Resolved Litigation: Received $100 Million in January 2024 and Entitled to Additional $25 Million Pending EMA Label Determination; Hundreds of Millions of Dollars in Potential Cost Savings and Additional Revenue Streams – – Recent Positive Interactions with FDA and EMA; Proposed Indications for Primary and Secondary Prevention of Cardiovascular Risk and Expan

Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00

Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00

BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50

BofA Securities downgraded Esperion Therapeutics from Buy to Neutral

JP Morgan resumed coverage of Esperion Therapeutics with a rating of Neutral

Northland Capital upgraded Esperion Therapeutics from Under Perform to Market Perform

BofA Securities upgraded Esperion Therapeutics from Underperform to Buy and set a new price target of $4.00 from $1.25 previously

Northland Capital downgraded Esperion Therapeutics from Market Perform to Under Perform and set a new price target of $1.00

BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $8.00 previously

Credit Suisse upgraded Esperion Therapeutics from Underperform to Neutral and set a new price target of $7.00 from $6.50 previously

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025. "We are pleased to welcome Robert to the Esperion Board, confident that his decades of leadership within the biopharmaceutical sector will be of great benefit as we engage in our co

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo

ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare p

– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure Additional Six-Month Patent Extension Through June 2031 – ANN ARBOR, Mich., March 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that following meetings with the U.S. Food and Drug Administration (FDA), it has gained alignment on a regulatory path forward for initiating Phase 3 studies of bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous and homozygous familial hyperchole

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement – – Announces Development of Triple Combination Products with Bempedoic Acid in the U.S. – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 04, 2025 (GLOBE

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ:ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion will receive an upfront and near-term milestone payments and will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price. In Australia, cardiovascular disease affects 1.2 million people and is a leading cause of death. In New Zealand, an estimated 175,000 adults are living with cardi

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company

ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the sha

– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025. "We are pleased to welcome Robert to the Esperion Board, confident that his decades of leadership within the biopharmaceutical sector will be of great benefit as we engage in our co

ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive management team and report to Sheldon Koenig, President and Chief Executive Officer. "We are thrilled to have Ben take on this expanded role on the Esperion leadership team with his promotion to CFO," said Sheldon Koenig, President and CEO of Esperion. "Ben has made significant contributions since joining the company in 2020, supporting our finance organization during a tra

ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion's Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders. "On behalf of the Esperion team and our directors, I am excited to welcome Marty as Chairperson of the Esperion Board. With his significant experience, Marty will provide additional leadership and strategic guidance to our Board as we continue to commercialize our medicines and advance our pipeline," said Sheldon Koenig, president and chief executive officer of Esperion. "Marty's expertise will be critical

ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern's retirement from the Board. "On behalf of the Esperion team and our directors, I am very pleased to welcome Stephen to the Esperion Board. Stephen's extensive experience as a senior business and legal executive for multiple public life science organizations will be a great asset for Esperion as we continue to commercialize our medicines and grow our pipeline," said Sheldon Koenig, president and ch

ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as a member of the Esperion executive leadership team effective immediately. In his role, Mr. Looker will lead the company's legal, compliance and ethics operations. "Mr. Looker is a highly experienced legal executive with broad pharmaceutical industry experience, and proven skill supporting clinical and commercial stage companies, and I welcome him to Esperion," said Sheldon Koenig, President and Chief Executive Officer of Esperion. "Mr. Looker's guidance and expertise will be especially valuabl

ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to welcome Seth to the Esperion board. His deep operational and commercial expertise will be especially relevant during this exciting and transformative time for our Company," said Sheldon Koenig, president and chief executive officer of Esperion. "Seth is a proven leader with a successful track record of developing and executing strategies to drive product growth, and we look forward to leveraging his counsel to

ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and Chief Executive Officer. Dr. Foody brings more than 20 years of experience in academic and preventive cardiology to ESPERION. "Dr. Foody is a global expert with extensive clinical and medical experience in preventive cardiology, global medical development and medical affairs, which adds greatly to the depth of our management team," said Sheldon Koenig, President and Chief Executive Officer of ESPERION. "J

-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR, Mich., May 17, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), today announced the appointment of Sheldon Koenig as president and chief executive officer and board member, effective immediately. With over 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space, Mr. Koenig has served as the company's chief operating officer since December 2020. He

ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M. Mayleben, president and chief executive officer of Esperion. Koenig joins the executive team of Esperion and will provide vision, leadership, strategy and operations expertise to further evolve Esperion into a commercial leader in cardiovascular medicine, as well as a highly successful, efficiently operated global company.   “Sheldon brings an incredible amount of relevant experience to our company that will be familiar to all of our sta